Oslo, 30 April 2024, the Board of Directors hereby calls for the Annual General
Meeting of Lytix Biopharma AS (the "Company") in Sandakerveien 130, 0484 Oslo,
Norway at 13:00 Hours (CEST) on 14 May 2024.

All documents regarding the Annual General Meeting are available at the
Company's website: www.lytixbiopharma.com.

For further information, please see the Company's website or contact CFO Gjest
Breistein. Please see below for contact details.

Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Phone: +47 952 60 512 

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.